+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Reduction of coronary events by pravastatin--is lowering low-density lipoprotein cholesterol the answer?



Reduction of coronary events by pravastatin--is lowering low-density lipoprotein cholesterol the answer?



American Journal of Cardiology 80(5): 683




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047202233

Download citation: RISBibTeXText

PMID: 9295011


Related references

Pravastatin reduces major coronary events in patients with low levels of both high-density lipoprotein cholesterol and low-density lipoprotein cholesterol Results from the LIPID Study. Journal of the American College of Cardiology 37(2 Supplement A): 262A, February, 2001

Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. European Heart Journal 25(9): 771-777, 2004

Lipid-lowering therapy with pravastatin reduces coronary plaque volume Role of high-density lipoprotein cholesterol containing apolipoprotein A-1. Journal of the American College of Cardiology 41(6 Supplement A): 296A, March 19, 2003

KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly. Atherosclerosis 220(2): 456-462, 2012

Comparison of low-density lipoprotein cholesterol lowering by pravastatin to <100 mg/dl versus >100 mg/dl on brachial artery vasoreactivity in patients with severe hypercholesterolemia and previous atherosclerotic events or diabetes mellitus. American Journal of Cardiology 89(7): 857-860, April 1, 2002

Comparison of low-density lipoprotein cholesterol lowering by pravastatin to <100 mg/dl versus >100 mg/dl on brachial artery vasoreactivity in patients with severe hypercholesterolemia and previous atherosclerotic events or diabetes mellitus. American Journal of Cardiology 89(7): 857-860, 2002

The low-density lipoprotein cholesterol-lowering effect of pravastatin and factors associated with achieving targeted low-density lipoprotein levels in an African-American population. Pharmacotherapy 20(12): 1454-1463, December, 2000

Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. American Journal of Cardiology 110(10): 1468-1476, 2013

Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment. Metabolism: Clinical and Experimental 54(6): 741-747, 2005

Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). American Journal of Cardiology 104(6): 829-834, 2009

Raising high-density lipoprotein cholesterol and lowering low-density lipoprotein cholesterol as adjunctive therapy to coronary artery revascularization. American Journal of Cardiology 86(12A): 28L-34L, December 21, 2000

Raising high-density lipoprotein cholesterol and lowering low-density lipoprotein cholesterol as adjunctive therapy to coronary artery revascularization. American Journal of Cardiology 86(12a): 28l-34l, 2001

Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology 90(7): 731-736, 2002